Literature DB >> 26460357

Diabetic nephropathy: Nonsteroidal MRA added to RAS blockade reduces albuminuria.

Matthew R Weir1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26460357     DOI： 10.1038/nrneph.2015.167

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  10 in total

Review 1.  Proteinuria should be used as a surrogate in CKD.

Authors:  Paolo Cravedi; Piero Ruggenenti; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2012-03-06       Impact factor: 28.314

Review 2.  Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.

Authors:  Thomas A Mavrakanas; Karim Gariani; Pierre-Yves Martin
Journal:  Eur J Intern Med       Date:  2013-12-04       Impact factor: 4.487

Review 3.  Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis.

Authors:  Hiddo J Lambers Heerspink; Tobias F Kröpelin; Jarno Hoekman; Dick de Zeeuw
Journal:  J Am Soc Nephrol       Date:  2014-11-24       Impact factor: 10.121

4.  Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study.

Authors:  Kasper Rossing; Katrine J Schjoedt; Ulla M Smidt; Frans Boomsma; Hans-Henrik Parving
Journal:  Diabetes Care       Date:  2005-09       Impact factor: 19.112

5.  Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.

Authors:  George L Bakris; Rajiv Agarwal; Juliana C Chan; Mark E Cooper; Ron T Gansevoort; Hermann Haller; Giuseppe Remuzzi; Peter Rossing; Roland E Schmieder; Christina Nowack; Peter Kolkhof; Amer Joseph; Alexander Pieper; Nina Kimmeskamp-Kirschbaum; Luis M Ruilope
Journal:  JAMA       Date:  2015-09-01       Impact factor: 56.272

6.  Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.

Authors:  Uzma F Mehdi; Beverley Adams-Huet; Philip Raskin; Gloria L Vega; Robert D Toto
Journal:  J Am Soc Nephrol       Date:  2009-11-19       Impact factor: 10.121

Review 7.  Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies.

Authors:  Bertram Pitt
Journal:  Mol Cell Endocrinol       Date:  2004-03-31       Impact factor: 4.102

8.  Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.

Authors:  Dick de Zeeuw; Giuseppe Remuzzi; Hans-Henrik Parving; William F Keane; Zhongxin Zhang; Shahnaz Shahinfar; Steve Snapinn; Mark E Cooper; William E Mitch; Barry M Brenner
Journal:  Circulation       Date:  2004-08-09       Impact factor: 29.690

9.  Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury.

Authors:  Peter Kolkhof; Martina Delbeck; Axel Kretschmer; Wolfram Steinke; Elke Hartmann; Lars Bärfacker; Frank Eitner; Barbara Albrecht-Küpper; Stefan Schäfer
Journal:  J Cardiovasc Pharmacol       Date:  2014-07       Impact factor: 3.105

10.  Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial.

Authors:  Bertram Pitt; Lars Kober; Piotr Ponikowski; Mihai Gheorghiade; Gerasimos Filippatos; Henry Krum; Christina Nowack; Peter Kolkhof; So-Young Kim; Faiez Zannad
Journal:  Eur Heart J       Date:  2013-05-27       Impact factor: 29.983
  10 in total
  2 in total

Review 1.  Recent advances in managing and understanding diabetic nephropathy.

Authors:  Sydney C W Tang; Gary C W Chan; Kar Neng Lai
Journal:  F1000Res       Date:  2016-05-31

2.  Tubular epithelial cell-derived extracellular vesicles induce macrophage glycolysis by stabilizing HIF-1α in diabetic kidney disease.

Authors:  Yijie Jia; Jiaqi Chen; Zhikang Zheng; Yuan Tao; Shuting Zhang; Meina Zou; Yanlin Yang; Meng Xue; Fang Hu; Yang Li; Qian Zhang; Yaoming Xue; Zongji Zheng
Journal:  Mol Med       Date:  2022-08-12       Impact factor: 6.376
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.